VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Esp protein
Preclinical
Biologic
U
University of British Columbia
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Chronic Wound
Withdrawn
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Chronic Wound
Preclinical
Withdrawn
Clinical
Trials by Indication
[1]
Chronic Wound
1 trial
Treatment of Chronic Wound Biofilms
Withdrawn
·
U
University of British Columbia
·
N/A
·
NCT01646502
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Esp protein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Esp protein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Esp protein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
University of British Columbia company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Preclinical
[1]
Company
U
University of British Columbia
Related News